CTKB

In the past six months (April 2026 - October 2026), Cytek Biosciences experienced several stock-impacting events. The Second Quarter 2026 Earnings Report on August 5, 2026, showed a 6% year-over-year revenue increase to $48.1 million and raised full-year 2026 revenue guidance, contributing to an approximately 18% stock climb. New product launches in Q2 2026, including the Cytek Borealis™ system and new Cytek Aurora™ Evo instrument configurations, fueled investor interest. A clinical flow cytometry collaboration with Sysmex Europe in early September 2026 positively impacted sentiment regarding the company's clinical growth strategy. The launch of a new Cytek Cloud analysis tool and subscription tier in late September 2026 underscored growth in the software ecosystem and recurring revenue, coinciding with strong upward stock movement. A patent infringement lawsuit verdict on August 21, 2026, found in Cytek's favor on three of four claims by Beckman Coulter, Inc., but found infringement on one claim under the doctrine of equivalents, awarding $20 million in lost profits and $36 million in royalties, which Cytek intends to challenge. On September 29, 2026, Cytek adopted amended bylaws requiring additional information from proponents of stockholder proposals and director nominees. Overall, CTKB shares rose approximately 15% over the trailing 30 days leading up to October 10, 2026, briefly trading above the consensus analyst price target before a pullback.